Fig 1.
Schematic outline of the 5-LOX pathway leading to the formation of leukotrienes.
The figure gives a schematic overview of the formation of 4-series leukotrines from arachidonic acid. The first step is catalysed by 5-lipoxygenase and 5-lipoxygenase activating protein (FLAP), which is also the rate-limiting step in the pathway. Next, leukotriene A4 is rapidly metabolised to either leukotriene B4 or the cysteinyl leukotrienes by leukotriene A4-hydroxylase or leukotriene C4-synthase, respectively.
Fig 2.
Flow chart of cohort selection process.
Table 1.
Baseline characteristics of the sub cohort and cases.
Table 2.
Distribution of genotypes for the ALOX-5 promoter polymorphism, according to number of tandem repeats (5'-GGGCGG-3').
Table 3.
Minor allele frequency for each SNP, selected from four candidate genes in the 5-LOX pathway.
Table 4.
Association of selected single nucleotide polymorphisms with incident myocardial infarction.
Table 5.
Association of selected haplotypes in FLAP and LTA4-H with incident myocardial infarction.
Table 6.
Multivariate test of haplotypes in FLAP and LTA4-H and association with incident myocardial infarction.